MCL Literature Feed
846 papers on mantle cell lymphoma from PubMed. Updated daily.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.
A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.
This review details diverse BTKi resistance mechanisms beyond BTK mutations, providing a framework for developing next-generation inhibitors and combination strategies to overcome treatment failure in MCL.
Single-cell RNA sequencing reveals pre-existing, minor therapy-resistant subclones at diagnosis, which are selected during treatment, explaining early relapse and highlighting cell-cycle dysregulation as a common resistance mechanism.
In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.